Azeliragon fails Phase III trial for Alzheimer’s disease: industry news round-up

Written by Sharon Salt, Editor

In this week’s industry news round-up we set the focus on Alzheimer’s disease (AD), with yet another clinical trial termination announced from vTv Therapeutics Inc. (NC, USA). On the other hand, Alzheimer’s researchers have proposed a novel framework for defining the disease, which focuses more on biological changes than clinical symptoms. Find out more in our selected highlights: New framework proposed for defining Alzheimer’s disease Azeliragon fails in Phase III trial for Alzheimer’s disease New framework proposed for defining Alzheimer’s disease Researchers have proposed a change in the way the AD is defined, with the new proposal being based on...

To view the full article, please register now for access

It's completely free